Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0LK8O
|
||||
Former ID |
DIB000860
|
||||
Drug Name |
LIFARIZINE HYDROCHLORIDE
|
||||
Synonyms |
BANM; Lifarizine hydrochloride < Rec INNM; RS-87476; 1-(Diphenylmethyl)-4-[5-methyl-2-(4-methylphenyl)-1H-imidazol-4-ylmethyl]piperazine trihydrochloride
|
||||
Indication | Nerve injury [ICD10:T14.4] | Discontinued in Phase 2 | [545611] | ||
Structure |
Download2D MOL |
||||
Target and Pathway | |||||
Target(s) | Calcium channel | Target Info | Blocker | [534011], [551871] | |
References | |||||
Ref 534011 | The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil. Br J Pharmacol. 1993 May;109(1):175-7. | ||||
Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.